These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

424 related items for PubMed ID: 27346355

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. AML1-ETO targets and suppresses cathepsin G, a serine protease, which is able to degrade AML1-ETO in t(8;21) acute myeloid leukemia.
    Jin W, Wu K, Li YZ, Yang WT, Zou B, Zhang F, Zhang J, Wang KK.
    Oncogene; 2013 Apr 11; 32(15):1978-87. PubMed ID: 22641217
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
    Mandoli A, Singh AA, Prange KHM, Tijchon E, Oerlemans M, Dirks R, Ter Huurne M, Wierenga ATJ, Janssen-Megens EM, Berentsen K, Sharifi N, Kim B, Matarese F, Nguyen LN, Hubner NC, Rao NA, van den Akker E, Altucci L, Vellenga E, Stunnenberg HG, Martens JHA.
    Cell Rep; 2016 Nov 15; 17(8):2087-2100. PubMed ID: 27851970
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia.
    Dou L, Yan F, Pang J, Zheng D, Li D, Gao L, Wang L, Xu Y, Shi J, Wang Q, Zhou L, Shen N, Singh P, Wang L, Li Y, Gao Y, Liu T, Chen C, Al-Kali A, Litzow MR, Chi YI, Bode AM, Liu C, Huang H, Liu D, Marcucci G, Liu S, Yu L.
    Nat Commun; 2019 Nov 07; 10(1):5051. PubMed ID: 31699991
    [Abstract] [Full Text] [Related]

  • 8. Epigenetic silencing of miR564 contributes to the leukemogenesis of t(8;21) acute myeloid leukemia.
    Yang E, Guan W, Gong D, Gao X, Han C, Zhang J, Wang H, Wang M, Li Y, Yu L.
    Clin Sci (Lond); 2020 Dec 11; 134(23):3079-3091. PubMed ID: 33201243
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Histone deacetylase 3 preferentially binds and collaborates with the transcription factor RUNX1 to repress AML1-ETO-dependent transcription in t(8;21) AML.
    Guo C, Li J, Steinauer N, Wong M, Wu B, Dickson A, Kalkum M, Zhang J.
    J Biol Chem; 2020 Mar 27; 295(13):4212-4223. PubMed ID: 32071087
    [Abstract] [Full Text] [Related]

  • 11. An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells.
    Zaidi SK, Perez AW, White ES, Lian JB, Stein JL, Stein GS.
    Oncotarget; 2017 Jun 20; 8(25):39994-40005. PubMed ID: 28611288
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Co-expression of AML1-ETO and PML-RARa following treatment of de novo acute myeloid leukemia with AML1-ETO.
    Zhang S, Zhou W, Li Y, Yu S, Xue M, Qiao Y, Jian J, Liu B, Wang D.
    Leuk Lymphoma; 2019 May 20; 60(5):1316-1319. PubMed ID: 30328750
    [No Abstract] [Full Text] [Related]

  • 14. Genome-wide studies identify a novel interplay between AML1 and AML1/ETO in t(8;21) acute myeloid leukemia.
    Li Y, Wang H, Wang X, Jin W, Tan Y, Fang H, Chen S, Chen Z, Wang K.
    Blood; 2016 Jan 14; 127(2):233-42. PubMed ID: 26546158
    [Abstract] [Full Text] [Related]

  • 15. AML1-ETO triggers epigenetic activation of early growth response gene l, inducing apoptosis in t(8;21) acute myeloid leukemia.
    Fu L, Huang W, Jing Y, Jiang M, Zhao Y, Shi J, Huang S, Xue X, Zhang Q, Tang J, Dou L, Wang L, Nervi C, Li Y, Yu L.
    FEBS J; 2014 Feb 14; 281(4):1123-31. PubMed ID: 24314118
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.
    Vangala RK, Heiss-Neumann MS, Rangatia JS, Singh SM, Schoch C, Tenen DG, Hiddemann W, Behre G.
    Blood; 2003 Jan 01; 101(1):270-7. PubMed ID: 12393465
    [Abstract] [Full Text] [Related]

  • 19. Identification of epigenetic modifiers essential for growth and survival of AML1/ETO-positive leukemia.
    Duque-Afonso J, Veratti P, Rehman UU, Herzog H, Mitschke J, Greve G, Eble J, Berberich B, Thomas J, Pantic M, Waterhouse M, Gentile G, Heidenreich O, Miething C, Lübbert M.
    Int J Cancer; 2024 Dec 01; 155(11):2068-2079. PubMed ID: 39146497
    [Abstract] [Full Text] [Related]

  • 20. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
    Liu S, Klisovic RB, Vukosavljevic T, Yu J, Paschka P, Huynh L, Pang J, Neviani P, Liu Z, Blum W, Chan KK, Perrotti D, Marcucci G.
    J Pharmacol Exp Ther; 2007 Jun 01; 321(3):953-60. PubMed ID: 17389244
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.